Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04322526 · ClinicalTrials.gov registry record · Phase 4
Study of Naltrexone-Induced Blockade of Antidepressant Effects
A Phase 4 study of Depression and Major Depressive Disorder, sponsored by Marta Peciña, MD PhD.
- Completed
- Registry status
- Phase 4
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT04322526 is a Phase 4 study of Depression and Major Depressive Disorder that has completed, run by Marta Peciña, MD PhD. The registered enrollment target is 25 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04322526, a Phase 4 study of Depression and Major Depressive Disorder, has completed, sponsored by Marta Peciña, MD PhD.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to determine whether antidepressant placebo effects and contextual cues broadly, can be blocked by one single dose of the µ-opioid antagonist naltrexone. To test this hypothesis, un-medicated, patients with MDD completed a randomized, double-blind, placebo-controlled, cross-over study of 50mg of the µ-opioid antagonist naltrexone or matching placebo, immediately before a Pharmaco-fMRI scanning session.
Conditions Studied
Interventions
- DRUG Placebo oral tablet
- DRUG Naltrexone 50 Mg Oral Tablet
Study Locations (1)
Pennsylvania
- Bellefield Towers - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2017-07-01 |
| Est. Completion | 2018-07-15 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04322526
The ClinicalTrials.gov registry entry for NCT04322526 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 786-participant average among 679 other Depression trials with a reported enrollment target (97% lower). The listed sponsor is Marta Peciña, MD PhD, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Depression appearing as the primary indexed condition, and to 2 interventions - of which Placebo oral tablet is the first listed.
NCT04322526 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04322526 about?
NCT04322526 is a clinical study titled "Study of Naltrexone-Induced Blockade of Antidepressant Effects". The goal of this study is to determine whether antidepressant placebo effects and contextual cues broadly, can be blocked by one single dose of the µ-opioid antagonist naltrexone. To test this hypothesis, un-medicated, patients with MDD completed a randomized, double-blind, placebo-controlled, cross...
What is the current status of trial NCT04322526?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 25 participants. The study started on 2017-07-01. Estimated completion is 2018-07-15.
What conditions does trial NCT04322526 study?
This clinical trial studies the following conditions: Depression, Major Depressive Disorder.
What interventions are being tested in trial NCT04322526?
The interventions under investigation include: Placebo oral tablet (DRUG), Naltrexone 50 Mg Oral Tablet (DRUG).
Who is sponsoring clinical trial NCT04322526?
This trial is sponsored by Marta Peciña, MD PhD, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04322526 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Identifying and Treating Depression in the Orthopaedic Trauma Population
RECRUITING · Phase 4
-
Dopaminergic Therapy for Anhedonia - 2
RECRUITING · Phase 4
-
Examining the Effects of Estradiol on Neural and Molecular Response to Reward
RECRUITING · Phase 4
-
Buspirone and Melatonin for Depression Following Traumatic Brain Injury
RECRUITING · Phase 4
-
Processes and Circuitry Underlying Threat Sensitivity as a Treatment Target for Co-morbid Anxiety and Depression
RECRUITING · Phase 4
-
Determining Optimal Treatment Sequences in Anxious Depression (DOTS-AD)
RECRUITING · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.